Wee1 Kinase As a Target for Cancer Therapy

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2013 Sep 10

PMID 24013427

Citations 144

Authors

Khanh Do

James H Doroshow

Shivaani Kummar

Affiliations

Soon will be listed here.

Abstract

Wee1, a protein kinase, regulates the G 2 checkpoint in response to DNA damage. Preclinical studies have elucidated the role of wee1 in DNA damage repair and the stabilization of replication forks, supporting the validity of wee1 inhibition as a viable therapeutic target in cancer. MK-1775, a selective and potent small-molecule inhibitor of wee1, is under clinical development as a potentiator of DNA damage caused by cytotoxic chemotherapies. We present a review of the role of wee1 in the cell cycle and DNA replication and summarize the clinical development to date of this novel class of anticancer agents.

Citing Articles

DGKα Enhances Tumorigenic Activity in Bladder Cancer Patients With Chronic Kidney Disease.

Takemoto K, Kobatake K, Hatayama T, Tasaka S, Okazaki M, Nakano Y Cancer Med. 2025; 14(5):e70710.

PMID: 40013327 PMC: 11865707. DOI: 10.1002/cam4.70710.

High WEE1 expression is independently linked to poor survival in multiple myeloma.

Simhal A, Firestone R, Oh J, Avutu V, Norton L, Hultcrantz M Blood Cancer J. 2025; 15(1):22.

PMID: 39979284 PMC: 11842801. DOI: 10.1038/s41408-025-01230-y.

Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers.

Kim D, Chung H, Liu W, Jeong K, Ozmen T, Ozmen F NPJ Precis Oncol. 2025; 9(1):3.

PMID: 39755818 PMC: 11700143. DOI: 10.1038/s41698-024-00787-4.

Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.

Hamilton E, Falchook G, Wang J, Fu S, Oza A, Imedio E Target Oncol. 2024; 19(6):879-892.

PMID: 39487373 PMC: 11557630. DOI: 10.1007/s11523-024-01102-8.

Pharmacoproteogenomic approach identifies on-target kinase inhibitors for cancer drug repositioning.

Noguchi R, Osaki J, Ono T, Adachi Y, Iwata S, Yoshimatsu Y In Vitro Cell Dev Biol Anim. 2024; 60(10):1200-1214.

PMID: 39422823 DOI: 10.1007/s11626-024-00983-3.

References

Garimella S, Rocca A, Lipkowitz S . WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Mol Cancer Res. 2011; 10(1):75-85. PMC: 3262068. DOI: 10.1158/1541-7786.MCR-11-0500. View

Iwai A, Bourboulia D, Mollapour M, Jensen-Taubman S, Lee S, Donnelly A . Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle. 2012; 11(19):3649-55. PMC: 3478315. DOI: 10.4161/cc.21926. View

Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M . Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009; 8(11):2992-3000. DOI: 10.1158/1535-7163.MCT-09-0463. View

Johnson N, Cai D, Kennedy R, Pathania S, Arora M, Li Y . Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. Mol Cell. 2009; 35(3):327-39. PMC: 3024055. DOI: 10.1016/j.molcel.2009.06.036. View

PosthumaDeBoer J, Wurdinger T, Graat H, van Beusechem V, Helder M, van Royen B . WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer. 2011; 11:156. PMC: 3103478. DOI: 10.1186/1471-2407-11-156. View

Jazayeri A, Falck J, Lukas C, Bartek J, Smith G, Lukas J . ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol. 2005; 8(1):37-45. DOI: 10.1038/ncb1337. View

Wang Y, Li J, Booher R, Kraker A, Lawrence T, Leopold W . Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001; 61(22):8211-7. View

Wang Y, Decker S, Sebolt-Leopold J . Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther. 2004; 3(3):305-13. DOI: 10.4161/cbt.3.3.697. View

Russell P, Nurse P . Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog. Cell. 1987; 49(4):559-67. DOI: 10.1016/0092-8674(87)90458-2. View

10.

Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N . MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther. 2010; 9(7):514-22. DOI: 10.4161/cbt.9.7.11115. View

11.

Guertin A, Li J, Liu Y, Hurd M, Schuller A, Long B . Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol Cancer Ther. 2013; 12(8):1442-52. DOI: 10.1158/1535-7163.MCT-13-0025. View

12.

Masaki T, Shiratori Y, Rengifo W, Igarashi K, Yamagata M, Kurokohchi K . Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology. 2003; 37(3):534-43. DOI: 10.1053/jhep.2003.50112. View

13.

Iorns E, Lord C, Grigoriadis A, McDonald S, Fenwick K, Mackay A . Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One. 2009; 4(4):e5120. PMC: 2663812. DOI: 10.1371/journal.pone.0005120. View

14.

Esashi F, Christ N, Gannon J, Liu Y, Hunt T, Jasin M . CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature. 2005; 434(7033):598-604. DOI: 10.1038/nature03404. View

15.

Helleday T . The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011; 5(4):387-93. PMC: 5528309. DOI: 10.1016/j.molonc.2011.07.001. View

16.

Magnussen G, Holm R, Emilsen E, Rosnes A, Slipicevic A, Florenes V . High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS One. 2012; 7(6):e38254. PMC: 3373567. DOI: 10.1371/journal.pone.0038254. View

17.

Kreahling J, Gemmer J, Reed D, Letson D, Bui M, Altiok S . MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther. 2011; 11(1):174-82. PMC: 4545500. DOI: 10.1158/1535-7163.MCT-11-0529. View

18.

Mir S, de Witt Hamer P, Krawczyk P, Balaj L, Claes A, Niers J . In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 2010; 18(3):244-57. PMC: 3115571. DOI: 10.1016/j.ccr.2010.08.011. View

19.

Haince J, McDonald D, Rodrigue A, Dery U, Masson J, Hendzel M . PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem. 2007; 283(2):1197-208. DOI: 10.1074/jbc.M706734200. View

20.

Jackson S, Bartek J . The DNA-damage response in human biology and disease. Nature. 2009; 461(7267):1071-8. PMC: 2906700. DOI: 10.1038/nature08467. View